Boxer Capital
Latest statistics and disclosures from Boxer Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RVMD, TYRA, NUVL, Beigene, CYTK, and represent 33.54% of Boxer Capital's stock portfolio.
- Added to shares of these 10 stocks: TIL (+$24M), KYMR (+$21M), NRIX (+$13M), QURE (+$11M), APGE (+$11M), TERN (+$6.3M), SRRK (+$6.0M), SMMT (+$5.5M), CGEM, BCAX.
- Started 12 new stock positions in APGE, TERN, BCAX, QURE, KYMR, TIL, NRIX, ZURA, SRRK, MRSN. SMMT, DBVT.
- Reduced shares in these 10 stocks: FATE (-$11M), ALLO (-$9.0M), NKTX (-$7.1M), PSTX (-$7.1M), AMLX, ABSI, PRLD, IPSC, Atara Biotherapeutics, Dbv Technologies S A.
- Sold out of its positions in ABSI, ALLO, AMLX, Atara Biotherapeutics, Dbv Technologies S A.
- Boxer Capital was a net buyer of stock by $65M.
- Boxer Capital has $2.0B in assets under management (AUM), dropping by 7.31%.
- Central Index Key (CIK): 0001465837
Tip: Access up to 7 years of quarterly data
Positions held by Boxer Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv

Portfolio Holdings for Boxer Capital
Boxer Capital holds 68 positions in its portfolio as reported in the September 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Revolution Medicines (RVMD) | 9.5 | $194M | 4.3M | 45.35 |
|
|
Tyra Biosciences (TYRA) | 7.4 | $152M | 6.4M | 23.51 |
|
|
Nuvalent Inc-a (NUVL) | 5.6 | $115M | 1.1M | 102.30 |
|
|
BeiGene Sponsored Adr | 5.5 | $112M | 500k | 224.51 |
|
|
Cytokinetics Com New (CYTK) | 5.4 | $111M | 2.1M | 52.80 |
|
|
Springworks Therapeutics (SWTX) | 5.4 | $110M | 3.4M | 32.04 |
|
|
Merus N V (MRUS) | 4.7 | $95M | 1.9M | 49.96 |
|
|
Sarepta Therapeutics (SRPT) | 4.0 | $81M | 650k | 124.89 |
|
|
Avidity Biosciences Ord (RNA) | 3.9 | $79M | 1.7M | 45.93 |
|
|
Ideaya Biosciences (IDYA) | 3.4 | $70M | 2.2M | 31.68 |
|
|
Tango Therapeutics (TNGX) | 3.1 | $63M | 8.2M | 7.70 |
|
|
Argenx SE Sponsored Adr (ARGX) | 2.7 | $54M | 100k | 542.08 |
|
|
Apellis Pharmaceuticals (APLS) | 2.4 | $50M | 1.7M | 28.84 |
|
|
Akero Therapeutics (AKRO) | 2.4 | $48M | 1.7M | 28.69 |
|
|
Anaptysbio Inc Common (ANAB) | 2.1 | $44M | 1.3M | 33.50 |
|
|
Axsome Therapeutics (AXSM) | 1.8 | $36M | 400k | 89.87 |
|
|
Iteos Therapeutics (ITOS) | 1.5 | $30M | 2.9M | 10.21 |
|
|
Legend Biotech Corp Sponsored Ads (LEGN) | 1.4 | $29M | 600k | 48.73 |
|
|
Geron Corporation (GERN) | 1.3 | $27M | 6.0M | 4.54 |
|
|
Third Harmonic Bio (THRD) | 1.3 | $27M | 2.0M | 13.55 |
|
|
Rocket Pharmaceuticals (RCKT) | 1.3 | $27M | 1.5M | 18.47 |
|
|
Arcus Biosciences Incorporated (RCUS) | 1.2 | $25M | 1.6M | 15.29 |
|
|
Instil Bio Com New (TIL) | 1.2 | $24M | NEW | 356k | 67.32 |
|
Xenon Pharmaceuticals (XENE) | 1.2 | $24M | 600k | 39.37 |
|
|
Immunovant (IMVT) | 1.2 | $24M | 825k | 28.51 |
|
|
Kymera Therapeutics (KYMR) | 1.0 | $21M | NEW | 450k | 47.33 |
|
Spyre Therapeutics Com New (SYRE) | 1.0 | $21M | 697k | 29.41 |
|
|
Kura Oncology (KURA) | 1.0 | $20M | 1.0M | 19.54 |
|
|
Kalvista Pharmaceuticals (KALV) | 0.9 | $18M | 1.6M | 11.58 |
|
|
Nkarta (NKTX) | 0.9 | $18M | -28% | 4.0M | 4.52 |
|
Oric Pharmaceuticals (ORIC) | 0.9 | $18M | 1.7M | 10.25 |
|
|
Structure Therapeutics Sponsored Ads (GPCR) | 0.9 | $18M | 400k | 43.89 |
|
|
Fate Therapeutics (FATE) | 0.9 | $17M | -39% | 5.0M | 3.50 |
|
Enliven Therapeutics (ELVN) | 0.8 | $17M | 671k | 25.54 |
|
|
Replimune Group (REPL) | 0.8 | $17M | 1.5M | 10.96 |
|
|
Day One Biopharmaceuticals I (DAWN) | 0.8 | $17M | 1.2M | 13.93 |
|
|
Cullinan Oncology (CGEM) | 0.7 | $15M | +37% | 908k | 16.74 |
|
Arvinas Ord (ARVN) | 0.7 | $15M | 609k | 24.63 |
|
|
Eliem Therapeutics (CLYM) | 0.7 | $13M | 2.6M | 5.09 |
|
|
Relay Therapeutics (RLAY) | 0.6 | $13M | 1.8M | 7.08 |
|
|
Nurix Therapeutics (NRIX) | 0.6 | $13M | NEW | 563k | 22.47 |
|
Prothena Corp SHS (PRTA) | 0.6 | $12M | 690k | 16.73 |
|
|
Uniqure NV SHS (QURE) | 0.5 | $11M | NEW | 2.2M | 4.93 |
|
Apogee Therapeutics (APGE) | 0.5 | $11M | NEW | 179k | 58.74 |
|
Olema Pharmaceuticals (OLMA) | 0.4 | $7.8M | 650k | 11.94 |
|
|
Iovance Biotherapeutics (IOVA) | 0.3 | $7.0M | 750k | 9.39 |
|
|
Century Therapeutics (IPSC) | 0.3 | $6.7M | -20% | 3.9M | 1.71 |
|
Jasper Therapeutics Com New (JSPR) | 0.3 | $6.6M | 350k | 18.81 |
|
|
Sana Biotechnology (SANA) | 0.3 | $6.4M | 1.5M | 4.16 |
|
|
Terns Pharmaceuticals (TERN) | 0.3 | $6.3M | NEW | 752k | 8.34 |
|
Scholar Rock Hldg Corp (SRRK) | 0.3 | $6.0M | NEW | 750k | 8.01 |
|
Poseida Therapeutics I (PSTX) | 0.3 | $5.7M | -55% | 2.0M | 2.86 |
|
Summit Therapeutics (SMMT) | 0.3 | $5.5M | NEW | 250k | 21.90 |
|
Engene Holdings (ENGN) | 0.2 | $4.8M | 728k | 6.60 |
|
|
Prelude Therapeutics (PRLD) | 0.2 | $3.5M | -33% | 1.7M | 2.07 |
|
Bicara Therapeutics (BCAX) | 0.2 | $3.4M | NEW | 135k | 25.47 |
|
Mersana Therapeutics (MRSN) | 0.2 | $3.4M | NEW | 1.8M | 1.89 |
|
Boundless Bio (BOLD) | 0.1 | $2.5M | 711k | 3.47 |
|
|
Black Diamond Therapeutics (BDTX) | 0.1 | $2.2M | 506k | 4.35 |
|
|
Zentalis Pharmaceuticals (ZNTL) | 0.1 | $1.7M | 450k | 3.68 |
|
|
Protara Therapeutics Com Stk (TARA) | 0.1 | $1.5M | 812k | 1.83 |
|
|
Health Sciences Acq Corp 2 (OBIO) | 0.1 | $1.2M | 238k | 5.14 |
|
|
Zura Bio Class A Ord Shs (ZURA) | 0.1 | $1.2M | NEW | 300k | 4.06 |
|
Bioatla (BCAB) | 0.1 | $1.2M | 686k | 1.76 |
|
|
Milestone Pharmaceuticals (MIST) | 0.0 | $470k | 309k | 1.52 |
|
|
DBV Technologies S A Sponsored Adr (DBVT) | 0.0 | $175k | NEW | 250k | 0.70 |
|
Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $26k | 267k | 0.10 |
|
|
Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $1.3k | 67k | 0.02 |
|
Past Filings by Boxer Capital
SEC 13F filings are viewable for Boxer Capital going back to 2015
- Boxer Capital 2024 Q3 filed Nov. 14, 2024
- Boxer Capital 2024 Q2 filed Aug. 14, 2024
- Boxer Capital 2024 Q1 filed May 15, 2024
- Boxer Capital 2023 Q4 filed Feb. 14, 2024
- Boxer Capital 2023 Q3 filed Nov. 14, 2023
- Boxer Capital 2023 Q2 filed Aug. 14, 2023
- Boxer Capital 2023 Q1 filed May 15, 2023
- Boxer Capital 2022 Q4 filed Feb. 14, 2023
- Boxer Capital 2022 Q3 filed Nov. 14, 2022
- Boxer Capital 2022 Q2 filed Aug. 15, 2022
- Boxer Capital 2022 Q1 filed May 16, 2022
- Boxer Capital 2021 Q4 filed Feb. 14, 2022
- Boxer Capital 2021 Q3 filed Nov. 15, 2021
- Boxer Capital 2021 Q2 filed Aug. 16, 2021
- Boxer Capital 2021 Q1 filed May 17, 2021
- Boxer Capital 2020 Q4 filed Feb. 16, 2021